Virpax Pharmaceuticals (VRPX) announced positive results from a beagle dog dose range finding study. Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The company continues to work towards its Investigational New Drug application and this was another important step towards that milestone. The DRF study was conducted to evaluate the tolerance of Probudur when administered by subcutaneous injection to beagle dogs in a dose escalating manner. All the dogs in the DRF study demonstrated positive tolerance to Probudur and no adverse effects were noted. The results of this study suggest that doses of LBL100 up to 90 mg/kg are well tolerated by beagle dogs.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRPX:
- Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
- Biotech Alert: Searches spiking for these stocks today
- Virpax Pharmaceuticals reports Molecular Envelope Technology human study data
- Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
- Virpax Pharmaceuticals Appoints Charn Deol as Independent Director